Table 5:

Efficacy Outcomes Stratified by Latent PVD and Other Subgroups

	Win Ratio	95% CI	P	HF event IRR	95% CI	P	Change in KCCQ	95% CI	P
No latent PVD with: (n sham/IASD)
No Pacemaker (152/161)	1.52	1.14, 2.00	0.004	0.49	0.25, 0.95	0.034	+5.9	1.5, 10.3	0.010
No HFmrEF¹ (172/186)	1.30	1.00, 1.69	0.050	0.58	0.34, 1.01	0.055	+4.8	0.7, 8.9	0.022
No LAE² (108/132)	1.21	0.88, 1.67	0.240	0.49	0.23, 1.04	0.063	+1.6	−3.4, 6.7	0.528
Pacemaker (30/39)	0.73	0.40, 1.32	0.295	1.47	0.62, 3.52	0.382	+3.5	−5.2, 13.2	0.423
HFmrEF¹ (10/14)	1.47	0.53, 4.11	0.461	6.88	0.65, 73.2	0.110	+14.5	−5.2, 34.2	0.140
LAE² (74/68)	1.38	0.92, 2.08	0.124	1.12	0.54, 2.33	0.766	+9.8	3.5, 16.1	0.003

Latent PVD with: (n sham/IASD)
No Pacemaker (83/67)	0.58	0.39, 0.86	0.008	2.39	1.13, 5.05	0.023	−6.4	−12.5, 0.3	0.041
No HFmrEF¹ (90/81)	0.60	0.42, 0.88	0.008	2.28	1.05, 4.96	0.038	−6.8	−12.5, −1.1	0.021
No LAE² (53/55)	0.57	0.36, 0.90	0.016	2.11	0.81, 5.51	0.126	−16.8	−16.8, −1.8	0.016
Pacemaker (17/21)	0.61	0.27, 1.37	0.230	3.61	0.48, 27.42	0.214	−6.9	−21.3, 7.6	0.342
HFmrEF¹ (17/10)	0.53	0.16, 1.77	0.304	6.78	0.59, 77.38	0.123	−1.0	−25.3, 23.4	0.933
LAE² (47/33)	0.66	0.38, 1.16	0.147	3.44	1.14, 10.40	0.029	−3.3	−12.1, 5.5	0.453

CI, confidence interval; HF, heart failure; IRR, incidence rate ratio; KCCQ, Kansas City Cardiomyopathy Questionnaire overall summary score; PVD, pulmonary vascular disease; IASD, interatrial shunt device; HFmrEF, heart failure with mildly reduced ejection fraction; LAE, left atrial enlargement

HFmrEF defined by EF 40–49%

LAE defined as values in the highest tertile (left atrial volume index>36.68 ml/m²)